<DOC>
	<DOCNO>NCT00003358</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness cisplatin plus gemcitabine treating patient refractory recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Cisplatin Gemcitabine Treating Patients With Refractory Recurrent Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose intraperitoneal ( IP ) gemcitabine give combination IP cisplatin patient refractory recurrent ovarian epithelial , fallopian tube , primary peritoneal cancer . II . Determine safety regimen patient population . III . Determine pharmacokinetics IP gemcitabine administer IP cisplatin . OUTLINE : This dose escalation study gemcitabine . Patients receive intraperitoneal cisplatin day 1 plus intraperitoneal gemcitabine day 1 , 8 , 15 . No treatment give day 22 . Courses repeat every 4 week . Patients receive 4 course therapy . Dose escalation gemcitabine continue cohort 3 patient maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose limit toxicity ( DLT ) . Patients follow every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : Approximately 3-24 patient accrue study .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document epithelial ovarian carcinoma fallopian tube cancer primary peritoneal cancer follow initial cytoreductive surgery chemotherapy least one cisplatin base chemotherapy regimen Must undergone second assessment procedure ( laparoscopy laparotomy ) within 8 week protocol entry , confirmation residual disease great 1.0 cm end procedure PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 3 time upper limit normal ( ULN ) SGOT le 3 time ULN Alkaline phosphatase less 3 time ULN Renal : Creatinine le 1.6 mg/dL Creatinine clearance least 50 mL/min Other : Must functioning implant subcutaneous intraperitoneal catheter No neuropathy grade III great prior chemotherapy No contraindication intraperitoneal therapy e.g. , intraabdominal infection widespread adhesion PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>